Literature DB >> 21701879

Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.

Pawel Domagala1, Dominika Wokolorczyk, Cezary Cybulski, Tomasz Huzarski, Jan Lubinski, Wenancjusz Domagala.   

Abstract

Germline mutations in BRCA1 were already linked to basal-like subtype of immunophenotypic molecular classification of breast cancer (BC). However, it is not known whether mutations in other BC susceptibility genes are associated with molecular subtypes of this cancer. We tested the hypothesis that distinct mutations in another BC susceptibility gene involved in DNA repair, i.e., CHEK2 may be associated with particular immunophenotypic molecular subtypes of this cancer. Two groups of patients: 1255 with BCs and 5496 healthy controls were genotyped for four CHEK2 mutations (I157T and three truncating mutations: 1100delC, IVS2 + 1G > A, del5395). BCs were tested by immunohistochemistry on tissue microarrays for ER, PR, HER-2, EGFR, and CK5/6 and were assigned to appropriate subtypes of immunophenotypic molecular classification. There was a significant association between CHEK2 mutations and the immunophenotypic molecular classification (P = 0.004). CHEK2-associated cancers were predominantly luminal (108/117 = 92.3%). CHEK2-I157T variant was associated with the luminal A subtype (P = 0.01), whereas CHEK2-truncating mutations were associated with the luminal B subtype (P = 0.005). Comparing the prevalence of CHEK2 mutations in BC with controls revealed that carriers of an I157T variant had OR of 1.80 for luminal A subtype and carriers of truncating mutations had OR of 6.26 for luminal B subtype of BC. To our knowledge, this is the first study showing that specific mutations in the same susceptibility gene are associated with different immunophenotypic molecular subtypes of BC. This association represents independent evidence supporting the biological significance of immunophenotypic molecular classification of BC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21701879     DOI: 10.1007/s10549-011-1635-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Authors:  Svasti Haricharan; Nindo Punturi; Purba Singh; Kimberly R Holloway; Meenakshi Anurag; Jacob Schmelz; Cheryl Schmidt; Jonathan T Lei; Vera Suman; Kelly Hunt; John A Olson; Jeremy Hoog; Shunqiang Li; Shixia Huang; Dean P Edwards; Shyam M Kavuri; Matthew N Bainbridge; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

Review 2.  Genotype/Phenotype correlations in patients with hereditary breast cancer.

Authors:  Maike Wittersheim; Reinhard Büttner; Birgid Markiefka
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

3.  Emerging Concepts in Breast Cancer Risk Prediction.

Authors:  Gretchen L Gierach; Xiaohong R Yang; Jonine D Figueroa; Mark E Sherman
Journal:  Curr Obstet Gynecol Rep       Date:  2013-03

4.  Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.

Authors:  Aglaya G Iyevleva; Svetlana N Aleksakhina; Anna P Sokolenko; Sofia V Baskina; Aigul R Venina; Elena I Anisimova; Ilya V Bizin; Alexandr O Ivantsov; Yana V Belysheva; Alexandra P Chernyakova; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Breast Cancer Res Treat       Date:  2022-01-12       Impact factor: 4.872

5.  Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.

Authors:  Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch
Journal:  J Clin Oncol       Date:  2021-10-21       Impact factor: 44.544

6.  Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.

Authors:  Muhammad U Rashid; Noor Muhammad; Saima Faisal; Asim Amin; Ute Hamann
Journal:  BMC Cancer       Date:  2013-06-27       Impact factor: 4.430

7.  Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.

Authors:  Pawel Domagala; Anna Jakubowska; Katarzyna Jaworska-Bieniek; Katarzyna Kaczmarek; Katarzyna Durda; Agnieszka Kurlapska; Cezary Cybulski; Jan Lubinski
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.

Authors:  Aneta Bąk; Hanna Janiszewska; Anna Junkiert-Czarnecka; Marta Heise; Maria Pilarska-Deltow; Ryszard Laskowski; Magdalena Pasińska; Olga Haus
Journal:  Hered Cancer Clin Pract       Date:  2014-04-08       Impact factor: 2.857

9.  Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines.

Authors:  Nandita Barnabas; Dalia Cohen
Journal:  Int J Breast Cancer       Date:  2013-01-16

10.  Rapid Detection Method for the Four Most Common CHEK2 Mutations Based on Melting Profile Analysis.

Authors:  Pawel Borun; Kacper Salanowski; Dariusz Godlewski; Jaroslaw Walkowiak; Andrzej Plawski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.